[go: up one dir, main page]

PL1711164T3 - Method of treating acute rhinosinusitis - Google Patents

Method of treating acute rhinosinusitis

Info

Publication number
PL1711164T3
PL1711164T3 PL05711867T PL05711867T PL1711164T3 PL 1711164 T3 PL1711164 T3 PL 1711164T3 PL 05711867 T PL05711867 T PL 05711867T PL 05711867 T PL05711867 T PL 05711867T PL 1711164 T3 PL1711164 T3 PL 1711164T3
Authority
PL
Poland
Prior art keywords
treating acute
acute rhinosinusitis
treating
disease
rhinosinusitis
Prior art date
Application number
PL05711867T
Other languages
Polish (pl)
Inventor
Melvyn Bloom
Melvyn Danzig
Patricia Rohane
Heribert Staudinger
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34825945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1711164(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL1711164T3 publication Critical patent/PL1711164T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

Disclosed are methods of treating rhinosinusitis of the upper airway passages in patients afflicted with said disease, which comprises administering at least once-a-day to the surfaces of said passages of said patients an amount of aerosolized particles of mometasone furoate as a monotherapy effective for treating said disease.
PL05711867T 2004-01-21 2005-01-19 Method of treating acute rhinosinusitis PL1711164T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53783004P 2004-01-21 2004-01-21
PCT/US2005/002105 WO2005072704A2 (en) 2004-01-21 2005-01-19 Method of treating acute rhinosinusitis
EP05711867A EP1711164B1 (en) 2004-01-21 2005-01-19 Method of treating acute rhinosinusitis

Publications (1)

Publication Number Publication Date
PL1711164T3 true PL1711164T3 (en) 2010-09-30

Family

ID=34825945

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05711867T PL1711164T3 (en) 2004-01-21 2005-01-19 Method of treating acute rhinosinusitis

Country Status (16)

Country Link
US (2) US20050186144A1 (en)
EP (2) EP2201936B1 (en)
JP (2) JP4976139B2 (en)
AT (1) ATE461693T1 (en)
CA (1) CA2554064A1 (en)
CY (1) CY1110620T1 (en)
DE (1) DE602005020113D1 (en)
DK (1) DK1711164T3 (en)
ES (2) ES2426957T3 (en)
HR (1) HRP20100208T8 (en)
MX (1) MXPA06008240A (en)
PL (1) PL1711164T3 (en)
PT (1) PT1711164E (en)
RS (1) RS51335B (en)
SI (1) SI1711164T1 (en)
WO (1) WO2005072704A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426957T3 (en) * 2004-01-21 2013-10-28 Merck Sharp & Dohme Corp. Acute Rhinosinusitis Treatment Procedure
WO2008047149A1 (en) * 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
RU2407558C1 (en) * 2009-07-02 2010-12-27 Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава") Method of treating acute rhinosinusitis in children
TWI411121B (en) * 2010-03-11 2013-10-01 Ind Tech Res Inst Method for manufacturing light absorbing layer and solar cell structure using same
EP3789022A1 (en) 2012-12-27 2021-03-10 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
JP7085485B2 (en) 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー Secretory P-glycoprotein is a non-invasive biomarker for chronic nasal sinusitis
WO2020198232A1 (en) 2019-03-25 2020-10-01 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
CN116209449A (en) * 2020-06-21 2023-06-02 麻省眼耳科医院 Verapamil and mometasone combination therapy for the treatment of chronic sinusitis
JP2024049405A (en) * 2021-02-22 2024-04-10 興和株式会社 New inhalants
EP4566595A1 (en) * 2023-12-07 2025-06-11 Bernhard Roth Combination preparation for the treatment of acute and chronic rhinosinusitis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4731447A (en) * 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
CA2111002C (en) 1991-06-10 2000-08-22 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
ATE339952T1 (en) * 1991-06-10 2006-10-15 Schering Corp HYDROCHLOROFLUOROCARBON-FREE AEROSOL FORMULATIONS
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (en) * 1994-01-27 1995-12-18 Schering Corp MOMETASONE FUROATE FOR THE TREATMENT OF LUNG DISEASES AND RESPIRATORY TRACT
US6068832A (en) 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6187765B1 (en) 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6297227B1 (en) * 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
SE9803770D0 (en) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6465581B1 (en) * 2001-01-24 2002-10-15 The Goodyear Tire & Rubber Company Silica reinforced rubber composition which contains stabilized unsymmetrical coupling agents and article of manufacture, including a tire, having at least one component comprised of such rubber composition
AR036358A1 (en) * 2001-08-28 2004-09-01 Schering Corp A DOSE INHALER MEASURES CONTAINING A SUSPENSION FORMULATION IN AEROSOL FOR INHALATION, A PROCESS FOR THE PRODUCTION OF THE FORMULATION, THE PRODUCT AND THE USE OF A FORMULATION FOR THE MANUFACTURE OF AN ASTHMA MEDICINAL PRODUCT
ES2388537T3 (en) * 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. Dosing inhaler containing an aerosol suspension formulation
US20040081625A1 (en) * 2002-10-21 2004-04-29 Schering Corporation Nasal formulations for the treatment of allergies
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
EP1684717A2 (en) * 2003-10-20 2006-08-02 Schering Corporation Pharmaceutical aerosol compositions
ES2426957T3 (en) * 2004-01-21 2013-10-28 Merck Sharp & Dohme Corp. Acute Rhinosinusitis Treatment Procedure
CN103429296A (en) 2010-12-13 2013-12-04 内诺斯蒂姆股份有限公司 Delivery catheter systems and methods
US9106249B1 (en) 2014-09-04 2015-08-11 Semtech Corporation Calibration of a time-interleaved analog-to-digital converter

Also Published As

Publication number Publication date
WO2005072704A3 (en) 2006-07-20
DK1711164T3 (en) 2010-07-19
DE602005020113D1 (en) 2010-05-06
EP2201936B1 (en) 2013-06-19
ES2340777T3 (en) 2010-06-09
RS51335B (en) 2011-02-28
ATE461693T1 (en) 2010-04-15
WO2005072704A2 (en) 2005-08-11
EP1711164A2 (en) 2006-10-18
CY1110620T1 (en) 2015-04-29
EP2201936A1 (en) 2010-06-30
US20090022671A1 (en) 2009-01-22
PT1711164E (en) 2010-06-28
EP1711164B1 (en) 2010-03-24
US20050186144A1 (en) 2005-08-25
SI1711164T1 (en) 2010-06-30
CA2554064A1 (en) 2005-08-11
JP2007518817A (en) 2007-07-12
HRP20100208T1 (en) 2010-05-31
MXPA06008240A (en) 2006-08-31
HRP20100208T8 (en) 2010-06-30
ES2426957T3 (en) 2013-10-28
JP4976139B2 (en) 2012-07-18
JP2008110991A (en) 2008-05-15

Similar Documents

Publication Publication Date Title
CY1110620T1 (en) METHOD OF TREATMENT OF ACUTE PARARRINOKOLPITIDAS
FR13C0034I1 (en)
WO2006078463A3 (en) Method for treating cardiovascular disease
EP4335510A3 (en) Method for inhibiting bone resorption
ATE530519T1 (en) CYCLOBUTYLAMINE DERIVATIVES
WO2003096977A3 (en) Methods of treating hepatitis
WO2007124461A8 (en) Glp-1 compounds
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
PT2383271E (en) Aminoquinolones as gsk-3 inhibitors
SI2380584T1 (en) Immunostimulatory method
JP2008535798A5 (en)
WO2007143607A3 (en) Method of treating atrophic vaginitis
UA85041C2 (en) Method for ileus treating
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP2023926A4 (en) Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
MX2009006541A (en) Treatment of prdc in pigs.
WO2007133941A3 (en) Therapeutic agent carrier
IL180931A0 (en) Medicaments for treating chronic respiratory disease
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
CY1112727T1 (en) CYCLUTOBUTYL PRODUCTS OF AMIN BENZOTHIJAZOLIS AND USE THESE AS PRESENTS OF HISTAMIN RECIPIENTS-3
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
WO2006047631A3 (en) Anti-mitotic anti-proliferative compounds
WO2006078713A3 (en) Methotrexate combinations for treating inflammatory diseases
WO2005051331A3 (en) Chaperone-based therapy for niemann-pick disease